On Thursday, LeMaitre Vascular earned an upgrade to its Relative Strength (RS) Rating, from 75 to 82.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating north of 80 as they launch their biggest runs.
LeMaitre Vascular is working on a consolidation with a 109.58 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company showed 29% earnings growth in its most recent report, while sales growth came in at 14%. Look for the next report on or around May 1.
LeMaitre Vascular earns the No. 10 rank among its peers in the Medical-Products industry group. Pro-Dex, Boston Scientific and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
